<DOC>
	<DOCNO>NCT03091751</DOCNO>
	<brief_summary>The goal non-randomized , multi-center study subject severe hereditary haemophilia B determine compare pharmacokinetic safety profile BeneFIX subject 2 prior pharmacokinetic assessment AlphaNine .</brief_summary>
	<brief_title>Efficacy Safety AlphaNine Versus BeneFIX Patients With Severe Hereditary Haemophilia B</brief_title>
	<detailed_description>Two pharmacokinetic assessment ( study ) carry subject previous clinical trial . The first pharmacokinetic study ( PK1 ) perform single dose AlphaNine . The second pharmacokinetic study ( PK2 ) perform follow 26 Weeks AlphaNine treatment PK1 . To compare AlphaNine BeneFIX , third pharmacokinetic study ( PK3 ) ( current study ) perform single dose BeneFIX administer follow 7- 15-day wash-out period .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Key Participated previous study `` Efficacy safety factor IX ( FIX ) contain Alphananine patient severe hereditary haemophilia B '' : Congenital deficiency Factor IX ( FIX ) FIX residual activity ≤2 % normal Had require FIXcontaining product past clinical record collect data assess reliable estimation least 150 treatment exposure day previous product Was able receive treatment 10 day 6month period Key Received dose FIX 7 day prior infusion FIX inhibitor level &gt; 0.5 Bethesda unit ( BU ) clinically relevant presence past ( ≥5 BU ) Active bleed moment infusion Had know allergic reaction BeneFIX component Exhibited symptom intercurrent infection ( ie , fever , chill , nausea ) time first infusion Had disease might affect distribution metabolism FIX could affect interpretation study ( noncontrolled diabetes mellitus ) Had noncontrolled arterial hypertension Had abnormal renal function ( creatinine &gt; 1.5 mg/dL ) Had document liver cirrhosis hepatic disorder alanine aminotransferase ( ALT ) level 2.5x upper limit normal ( ULN ) Prevision concomitantly treat FIXcontaining product Had condition might affect subject compliance ( survivallimiting [ 2 year time ] disease , alcohol drug abuse , etc . ) Unable provide storage plasma sample first dose BeneFIX</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Factor IX ( FIX )</keyword>
</DOC>